Response to 'The end of the dosage of 6 Thioguanine nucleotides? Not so sure…'

J Crohns Colitis. 2018 Jan 5;12(1):127. doi: 10.1093/ecco-jcc/jjx134.

Authors

Akbar K Waljee^{1

2}, Kay Sauder², Anand Patel³, Sandeep Segar³, Yiwei Zhang⁴, Ji Zhu⁴, Ryan W Stidham², Ulysses Balis⁵, Peter D R Higgins²

Affiliations

¹ Department of Veterans Affairs Center for Clinical Management Research, Ann Arbor, MI, USA.
² Division of Gastroenterology, Department of Internal Medicine, University of Michigan, MI, USA.
³ Department of Internal Medicine, University of Michigan, MI, USA.
⁴ Department of Statistics, University of Michigan, MI, USA.
⁵ Department of Pathology, University of Michigan, MI, USA.

No abstract available

Publication types

Letter

MeSH terms

Drug Dosage Calculations
Drug Monitoring / methods*
Gastrointestinal Agents / administration & dosage
Gastrointestinal Agents / pharmacokinetics
Guanine Nucleotides* / administration & dosage
Guanine Nucleotides* / pharmacokinetics
Humans
Inflammatory Bowel Diseases / drug therapy*
Thionucleotides* / administration & dosage
Thionucleotides* / pharmacokinetics

Substances

Gastrointestinal Agents
Guanine Nucleotides
Thionucleotides
6-thioguanylic acid

Grants and funding

K23 DK101687/DK/NIDDK NIH HHS/United States